In normal cells, the ABC transporters prevent the intracellular accumulation of potentially toxic endogenous and xenobiotic compounds; however, in cancer cells, the overexpression of these transporters significantly reduces the intracellular concentration of the substrate anticancer drug, producing desensitization, and eventually, resistance to drugs with distinct structures and mechanisms of action. This evidence concerns the gene ABCG2 and cancer.